Bolt Biotherapeutics Inc
Veridion Score
Composite trend over time
Why is BOLT moving today?
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for BOLT.
BOLT insider activity
Bolt Biotherapeutics Inc
No multi-insider buying cluster in the last 90 days
Net buying: $1K across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-02-04 | 2025-12-05 | Quinn William P. | Insider | buy | $4.61 | 125 | 2,313 | $576 | SEC Form 4 |
| 2026-02-04 | 2025-12-05 | Nemec Sarah | Insider | buy | $4.61 | 125 | 1,415 | $576 | SEC Form 4 |
BOLT contract awards, year to date.
Public federal awards linked to this ticker.
BOLT lobbying filings, year to date.
Registered lobbying filings matched to Bolt Biotherapeutics Inc.